Martin Ullmann

<scp>AURIEL</scp> ‐PsO: a randomized, double‐blind phase <scp>III</scp> equivalence trial to demonstrate the clinical similarity of the proposed biosimilar <scp>MSB</scp> 11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis

Jana Hercogová, Kim Papp, V. Chyrok et al. · British Journal of Dermatology · 2019 · 63 citations · Full text

2016 White Paper on Recent Issues in Bioanalysis: Focus on Biomarker Assay Validation (BAV): (Part 3 – Lba, Biomarkers and Immunogenicity)

Susan Richards, Lakshmi Amaravadi, Renuka Pillutla et al. · Bioanalysis · 2016 · 58 citations · Full text

Engineering, White Paper, Immunology +33

Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira^® in healthy subjects

Elizabeth Hyland, Tim Mant, Pantelis Vlachos et al. · British Journal of Clinical Pharmacology · 2016 · 48 citations · Full text

Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis

Christopher J Edwards, Joëlle Monnet, Martin Ullmann et al. · Clinical Rheumatology · 2019 · 30 citations · Full text

2023 White Paper on Recent Issues in Bioanalysis: ISR for ADA Assays, the Rise of dPCR vs qPCR, International Reference Standards for Vaccine Assays, Anti-AAV TAb Post-Dose Assessment, NanoString Validation, ELISpot as Gold Standard <u>(Part 3</u> – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity &amp; Technologies; Biotherapeutics Immunogenicity &amp; Risk Assessment; ADA/NAb Assay/Reporting Harmonization)

Johanna Mora, Rachel Palmer, Leslie Wagner et al. · Bioanalysis · 2024 · 16 citations · Full text